Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

Lipid nanoparticles (LNPs) are a potent delivery technology that have made it possible for
the recent clinical breakthroughs in mRNA therapeutics and vaccines. A key challenge to the …

COVID-19 vaccines have been developed with unprecedented speed which would not have
been possible without decades of fundamental research on delivery nanotechnology. Lipid …